Class Action Filed Against UroGen Pharma Ltd. (URGN) - July 28, 2025 Deadline to Join - Contact The Gross Law Firm

Core Viewpoint - UroGen Pharma Ltd. is facing a class action lawsuit due to allegations of misleading statements regarding the effectiveness of its lead pipeline product, UGN-102, during the class period from July 27, 2023, to May 15, 2025 [2] Group 1: Allegations - The complaint claims that the ENVISION clinical study was inadequately designed, lacking a concurrent control arm, which undermined its ability to demonstrate substantial evidence of UGN-102's effectiveness [2] - UroGen Pharma allegedly ignored FDA warnings about the study design, leading to a significant risk that the New Drug Application (NDA) for UGN-102 would not be approved [2] - Positive statements made by the company regarding its business and prospects were reportedly misleading and lacked a reasonable basis due to the aforementioned issues [2] Group 2: Class Action Details - Shareholders who purchased URGN shares during the specified class period are encouraged to register for the class action, with a deadline set for July 28, 2025 [3] - Upon registration, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3] - There is no cost or obligation for shareholders to participate in the class action [3] Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4]